Skip to main
TVGN
TVGN logo

TVGN Stock Forecast & Price Target

TVGN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tevogen Bio Holdings Inc. showcases significant potential through its innovative platform technology, which not only targets infectious diseases but also opens avenues for treating solid tumors and autoimmune diseases, thereby expanding its total addressable market. The company's rapid transition from discovery to the clinic in just 18 months highlights its operational efficiency and ability to convert scientific advancements into practical clinical offerings. Additionally, the development of TVGN 489 provides a crucial benefit for cancer patients facing challenges with SARS-CoV-2, ensuring continuity of oncologic care during viral infections.

Bears say

Tevogen Bio Holdings may face significant challenges due to its reliance on traditional antiviral strategies, which have proven to be less effective in certain patient populations, potentially undermining the success of its therapeutic offerings. The company's focus on patients experiencing treatment delays in critical areas such as hematology-oncology and severe rheumatologic conditions raises concerns about negative outcomes that could impact patient retention and treatment efficacy. Additionally, while Tevogen boasts manufacturing efficiencies compared to traditional CAR-T approaches, the broader market's emphasis on evolving viral targets and the associated risks of diminished efficacy further complicate its competitive positioning in the immunotherapy landscape.

TVGN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Semper Paratus Acquisition Corp (TVGN) Forecast

Analysts have given TVGN a Strong Buy based on their latest research and market trends.

According to 1 analysts, TVGN has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Semper Paratus Acquisition Corp (TVGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.